Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Coignard, Juliette
  • Beesley, Jonathan
  • O'Mara, Tracy A.
  • Diez Gibert, Orland
  • Lopez-Fernandez, Adrià
  • Dennis, Joe
  • Tyrer, Jonathan
  • Lush, Michael
Càncer de mama; Genètica del càncer; Factors de risc, Cáncer de mama; Genética del cáncer; Factores de riesgo, Breast cancer; Cancer genetics; Risk factors, Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime
  • Ortiz‑Barahona, Vanessa
  • Castro de Moura, Manuel
  • Martínez‑Cardús, Anna
  • Llinàs‑Arias, Pere
  • Soler, Marta
  • Arias Piñeiro, Alexandra
  • Cuartas Maza, Ma Isabel
  • Seoane Suarez, Joan
Resultado clínico; Epitranscriptómica; Glioma, Clinical outcome; Epitranscriptomics; Glioma, Resultat clínic; Epitranscriptòmica; Glioma, Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease., This work was supported by a European Research Council (ERC) Advanced Grant under the European Community’s Seventh Framework Program (FP7/2007-2013)/ERC Grant Agreement No. 268626—EPINORC project (to M. Esteller), the Ministerio de Economía y Competitividad (MINECO) under Grant No. SAF2014-55000-R (to M. Esteller) and the Instituto de Salud Carlos III (ISCIII), under the FIS PI16/01278 Project (to J. Seoane), the Integrated Project of Excellence no. PIE13/00022 (ONCOPROFILE) (to M. Esteller), CIBER 2016 CB16/12/00312 (CIBERONC) (to M. Esteller), co-financed by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF, the AGAUR—Catalan Government (Project No. 2009SGR1315 and 2014SGR633) (to M. Esteller), the Cellex Foundation (to M. Esteller), Obra Social “La Caixa” (to M. Esteller), the CERCA Program and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) (to M. Esteller) and a grant from the National Health and Medical Research Council of Australia (APP1061551, to TP). M.W. Boudreau is a member of the NIH Chemistry-Biology Interface Training Program (T32-GM070421).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine

  • Castellsagué, Joan|||0000-0002-2579-3137
  • Gel, Bernat|||0000-0001-8878-349X
  • Fernández-Rodríguez, Juana
  • Llatjós, Roger
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Pérez-Sidelnikova, Diana
  • Garcia del Muro, Xavier|||0000-0001-5571-2847
  • Viñals, Joan Maria
  • Vidal, August|||0000-0001-5727-2099
  • Valdés-Mas, Rafael
  • Terribas, Ernest
  • López-Doriga, Adriana
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Capella, Gabriel|||0000-0002-4669-7320
  • Puente, Xose S.|||0000-0001-9525-1483
  • Serra, Eduard|||0000-0003-2895-9857
  • Villanueva Garatachea, Alberto
  • Lázaro García, Conxi|||0000-0002-7198-5906
Malignant peripheral nerve sheath tumors (MPNSTs) are soft-tissue sarcomas that can arise either sporadically or in association with neurofibromatosis type 1 (NF1). These aggressive malignancies confer poor survival, with no effective therapy available. We present the generation and characterization of five distinct MPNST orthoxenograft models for preclinical testing and personalized medicine. Four of the models are patient-derived tumor xenografts (PDTX), two independent MPNSTs from the same NF1 patient and two from different sporadic patients. The fifth model is an orthoxenograft derived from an NF1-related MPNST cell line. All MPNST orthoxenografts were generated by tumor implantation, or cell line injection, next to the sciatic nerve of nude mice, and were perpetuated by 7-10 mouse-to-mouse passages. The models reliably recapitulate the histopathological properties of their parental primary tumors. They also mimic distal dissemination properties in mice. Human stroma was rapidly lost after MPNST engraftment and replaced by murine stroma, which facilitated genomic tumor characterization. Compatible with an origin in a catastrophic event and subsequent genome stabilization, MPNST contained highly altered genomes that remained remarkably stable in orthoxenograft establishment and along passages. Mutational frequency and type of somatic point mutations were highly variable among the different MPNSTs modeled, but very consistent when comparing primary tumors with matched orthoxenografts generated. Unsupervised cluster analysis and principal component analysis (PCA) using an MPNST expression signature of ~1,000 genes grouped together all primary tumor-orthoxenograft pairs. Our work points to differences in the engraftment process of primary tumors compared with the engraftment of established cell lines. Following standardization and extensive characterization and validation, the orthoxenograft models were used for initial preclinical drug testing. Sorafenib (a BRAF inhibitor), in combination with doxorubicin or rapamycin, was found to be the most effective treatment for reducing MPNST growth. The development of genomically well-characterized preclinical models for MPNST allowed the evaluation of novel therapeutic strategies for personalized medicine.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

  • Nogales, Vanesa
  • Reinhold, William C.
  • Varma, Sudhir
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Moutinho, Catia|||0000-0003-3885-0847
  • Moran, S.|||0000-0003-4192-8983
  • Heyn, Holger|||0000-0002-3276-1889
  • Sebio, Ana|||0000-0003-3333-2370
  • Barnadas i Molins, Agustí|||0000-0002-0429-1349
  • Pommier, Yves
  • Esteller, M.|||0000-0003-4490-6093
Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly used cancer chemotherapy drugs, but very few specific molecular and cellular markers predicting differential sensitivity to these agents in a given tumor type have been clearly identified. Epigenetic gene silencing is increasingly being recognized as a factor conferring distinct tumoral drug sensitivity, so we have used a comprehensive DNA methylation microarray platform to interrogate the widely characterized NCI60 panel of human cancer cell lines with respect to CpG methylation status and cisplatin/carboplatin sensitivity. Using this approach, we have found promoter CpG island hypermethylation-associated silencing of the putative DNA/RNA helicase Schlafen-11 (SLFN11) to be associated with increased resistance to platinum compounds. We have also experimentally validated these findings in vitro. In this setting, we also identified the BRCA1 interacting DHX9 RNA helicase (also known as RHA) as a protein partner for SLFN11, suggesting a mechanistic pathway for the observed chemoresistance effect. Most importantly, we have been able to extend these findings clinically, following the observation that those patients with ovarian and non-small cell lung cancer carrying SLFN11 hypermethylation had a poor response to both cisplatin and carboplatin treatments. Overall, these results identify SLFN11 epigenetic inactivation as a predictor of resistance to platinum drugs in human cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cancer network activity associated with therapeutic response and synergism

  • Serra-Musach, Jordi
  • Mateo, Francesca|||0000-0002-2342-7010
  • Capdevila Busquets, Eva
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Zhang, Xiaohu
  • Guha, Raj
  • Thomas, Craig J.
  • Grueso, Judit|||0000-0003-1093-7940
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Jaeger, Samira
  • Heyn, Holger|||0000-0002-3276-1889
  • Vizoso, Miguel
  • Pérez Montero, Hector|||0000-0002-9756-5088
  • Cordero, Alex
  • González Suarez, Eva
  • Esteller, M.|||0000-0003-4490-6093
  • Moreno-Bueno, Gema
  • Tjärnberg, Andreas
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Serra, Violeta|||0000-0001-6620-1065
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Benson, Mikael
  • Gustafsson, Mika
  • Ferrer Massot, Marc|||0000-0003-0046-1301
  • Aloy, Patrick|||0000-0002-3557-0236
  • Pujana, Miguel Angel|||0000-0003-3222-4044
Cancer patients often show no or only modest benefit from a given therapy. This major problem in oncology is generally attributed to the lack of specific predictive biomarkers, yet a global measure of cancer cell activity may support a comprehensive mechanistic understanding of therapy efficacy. We reasoned that network analysis of omic data could help to achieve this goal. A measure of "cancer network activity" (CNA) was implemented based on a previously defined network feature of communicability. The network nodes and edges corresponded to human proteins and experimentally identified interactions, respectively. The edges were weighted proportionally to the expression of the genes encoding for the corresponding proteins and relative to the number of direct interactors. The gene expression data corresponded to the basal conditions of 595 human cancer cell lines. Therapeutic responses corresponded to the impairment of cell viability measured by the half maximal inhibitory concentration (IC) of 130 drugs approved or under clinical development. Gene ontology, signaling pathway, and transcription factor-binding annotations were taken from public repositories. Predicted synergies were assessed by determining the viability of four breast cancer cell lines and by applying two different analytical methods. The effects of drug classes were associated with CNAs formed by different cell lines. CNAs also differentiate target families and effector pathways. Proteins that occupy a central position in the network largely contribute to CNA. Known key cancer-associated biological processes, signaling pathways, and master regulators also contribute to CNA. Moreover, the major cancer drivers frequently mediate CNA and therapeutic differences. Cell-based assays centered on these differences and using uncorrelated drug effects reveals novel synergistic combinations for the treatment of breast cancer dependent on PI3K-mTOR signaling. Cancer therapeutic responses can be predicted on the basis of a systems-level analysis of molecular interactions and gene expression. Fundamental cancer processes, pathways, and drivers contribute to this feature, which can also be exploited to predict precise synergistic drug combinations. The online version of this article (doi:10.1186/s13073-016-0340-x) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia

  • Anadón, C.
  • van Tetering, G.
  • Ferreira, H. J.
  • Moutinho, Catia|||0000-0003-3885-0847
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Soler, Marta|||0000-0002-6656-957X
  • Heyn, Holger|||0000-0002-3276-1889
  • Moran, S.|||0000-0003-4192-8983
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Setien, F.
  • Vidal, A.
  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Guil, Sonia|||0000-0002-2257-3331
  • Esteller, M.|||0000-0003-4490-6093
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Quiles, Francisco
  • Ruiz de Garibay, G.
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Prados-Carvajal, Rosario
  • Fernández-Rodríguez, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Diez, Orland|||0000-0001-7339-0570
  • Benitez, Javier|||0000-0002-0923-7202
  • Salinas, Monica
  • Teule, Alex|||0000-0003-0028-7200
  • Brunet, Joan|||0000-0003-1945-3512
  • Radice, Paolo|||0000-0001-6298-4111
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose P.
  • Lázaro, Coxi
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Benchmarking of Whole Exome Sequencing and Ad Hoc Designed Panels for Genetic Testing of Hereditary Cancer

  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Tonda, Raúl
  • Gausachs, Mireia
  • Trotta, Jean-Rémi
  • Castellanos, Elisabeth|||0000-0002-8133-5325
  • López-Doriga, Adriana
  • Teule, Alex|||0000-0003-0028-7200
  • Tornero, Eva
  • Del Valle, Jesús|||0000-0003-3607-7045
  • Gel, Bernat|||0000-0001-8878-349X
  • Gut, Marta|||0000-0002-4063-7159
  • Pineda, Marta|||0000-0002-5403-5845
  • González, Sara
  • Menéndez, Mireia
  • Navarro, Matilde
  • Capella, Gabriel|||0000-0002-4669-7320
  • Gut, Ivo|||0000-0001-7219-632X
  • Serra, Eduard|||0000-0003-2895-9857
  • Brunet, Joan|||0000-0003-1945-3512
  • Beltran i Agulló, Sergi|||0000-0002-2810-3445
  • Lázaro García, Conxi|||0000-0002-7198-5906
Next generation sequencing panels have been developed for hereditary cancer, although there is some debate about their cost-effectiveness compared to exome sequencing. The performance of two panels is compared to exome sequencing. Twenty-four patients were selected: ten with identified mutations (control set) and fourteen suspicious of hereditary cancer but with no mutation (discovery set). TruSight Cancer (94 genes) and a custom panel (122 genes) were assessed alongside exome sequencing. Eightythree genes were targeted by the two panels and exome sequencing. More than 99% of bases had a read depth of over 30x in the panels, whereas exome sequencing covered 94%. Variant calling with standard settings identified the 10 mutations in the control set, with the exception of MSH6 c.255dupC using TruSight Cancer. In the discovery set, 240 unique non-silent coding and canonic splice-site variants were identified in the panel genes, 7 of them putatively pathogenic (in ATM, BARD1, CHEK2, ERCC3, FANCL, FANCM, MSH2). The three approaches identified a similar number of variants in the shared genes. Exomes were more expensive than panels but provided additional data. In terms of cost and depth, panels are a suitable option for genetic diagnostics, although exomes also identify variants in non-targeted genes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Felip, Enriqueta|||0000-0002-7620-0098
  • Matito, Judit|||0000-0001-7560-7737
  • Mereu, Elisabetta|||0000-0001-6101-8472
  • Navarro, Alejandro|||0000-0001-5903-270X
  • Cedrés, Susana|||0000-0002-0648-7978
  • Pardo Aranda, Nuria
  • Martinez de Castro, Ana
  • Remon, Jordin
  • Miquel, J. M.
  • Guillaumet-Adkins, A.
  • Nadal, Ernest|||0000-0002-9674-5554
  • Rodriguez Esteban, Gustavo
  • Arqués Casamitjana, Oriol
  • Fasani, Roberta|||0000-0003-1630-9988
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Heyn, Holger|||0000-0002-3276-1889
  • Villanueva Garatachea, Alberto
  • Palmer, Héctor G.
  • Vivancos, Ana|||0000-0003-2888-6512
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR -mutant harboring T790M. Different mechanisms of acquired resistance to third-generation EGFR-TKIs have been proposed. It is therefore crucial to identify new and effective strategies to overcome successive acquired mechanisms of resistance. For Amplicon-seq analysis, samples from the index patient (primary and metastasis lesions at different timepoints) as well as the patient-derived orthotopic xenograft tumors corresponding to the different treatment arms were used. All samples were formalin-fixed paraffin-embedded, selected and evaluated by a pathologist. For droplet digital PCR, 20 patients diagnosed with NSCLC at baseline or progression to different lines of TKI therapies were selected. Formalin-fixed paraffin-embedded blocks corresponding to either primary tumor or metastasis specimens were used for analysis. For single-cell analysis, orthotopically grown metastases were dissected from the brain of an athymic nu/nu mouse and cryopreserved at -80°C. In a brain metastasis lesion from a NSCLC patient presenting an EGFR T790M mutation, we detected MET gene amplification after prolonged treatment with osimertinib. Importantly, the combination of capmatinib (c-MET inhibitor) and afatinib (ErbB-1/2/4 inhibitor) completely suppressed tumor growth in mice orthotopically injected with cells derived from this brain metastasis. In those mice treated with capmatinib or afatinib as monotherapy, we observed the emergence of KRAS G12C clones. Single-cell gene expression analyses also revealed intratumor heterogeneity, indicating the presence of a KRAS -driven subclone. We also detected low-frequent KRAS G12C alleles in patients treated with various EGFR-TKIs. Acquired resistance to subsequent EGFR-TKI treatment lines in EGFR -mutant lung cancer patients may induce genetic plasticity. We assess the biological insights of tumor heterogeneity in an osimertinib-resistant tumor with acquired MET- amplification and propose new treatment strategies in this situation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime|||0000-0003-1013-4128
  • Ortiz-Barahona, V.
  • de Moura, M. C.
  • Martínez Cardús, Anna|||0000-0002-3937-8794
  • Llinàs-Arias, Pere|||0000-0002-3666-0532
  • Soler, Marta|||0000-0002-6656-957X
  • Nachmani, D.
  • Pelletier, Joffrey|||0000-0001-9174-044X
  • Schumann, U.
  • Calleja-Cervantes, María Eréndira|||0000-0003-0688-0793
  • Moran, S.|||0000-0003-4192-8983
  • Guil, Sonia|||0000-0002-2257-3331
  • Bueno-Costa, Alberto|||0000-0001-8700-2540
  • Piñeyro, David|||0000-0001-5633-3339
  • Perez-Salvia, Montserrat
  • Rosselló-Tortella, M.
  • Piqué, Laia
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • De La Torre Gómez, Gisela Carolina|||0000-0001-9363-291X
  • Vidal, August|||0000-0001-5727-2099
  • Martínez-Iniesta, M.
  • Martín-Tejera, J. F.
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Arias, Alexandra
  • Cuartas, Isabel
  • Aransay, Ana M.|||0000-0002-8271-612X
  • La Madrid, A. M.
  • Carcaboso, Angel M.|||0000-0002-8485-426X
  • Santa-Maria, V.
  • Mora, J.
  • Fernández, Agustín F.|||0000-0002-3792-4085
  • Fraga, M. F.
  • Aldecoa, Iban|||0000-0001-5774-7453
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Graus Ribas, Francesc|||0000-0002-8924-8322
  • Vidal, Noemí|||0000-0002-2852-6667
  • Martinez, Fina|||0000-0002-0940-1025
  • Tortosa, Avelina|||0000-0002-9080-2976
  • Carrato, Cristina|||0000-0002-1953-8287
  • Balañá, Carmen|||0000-0003-0771-0390
  • Boudreau, M. W.
  • Hergenrother, P. J.
  • Kötter, P.
  • Entian, K. D.
  • Hench, Jürgen
  • Frank, Stephan|||0000-0001-6165-0187
  • Mansouri, S.
  • Zadeh, G.
  • Dans, P. D.
  • Orozco López, Modesto|||0000-0002-8608-3278
  • Thomas, Gareth J.
  • Blanco, Sandra
  • Seoane Suárez, Joan|||0000-0002-6541-5974
  • Preiss, T.
  • Pandolfi, P. P.
  • Esteller, M.|||0000-0003-4490-6093
Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma, implications for biomarker-driven clinical trials

  • Montal, Robert
  • Andreu-Oller, Carmen|||0000-0001-7405-9134
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Esteban-Fabró, Roger
  • Moran, S.|||0000-0003-4192-8983
  • Montironi, Carla|||0000-0002-1453-2193
  • Moeini, Agrin
  • Pinyol, Roser|||0000-0002-0288-6314
  • Peix, Judit
  • Cabellos, Laia
  • Villanueva, Augusto|||0000-0003-3585-3727
  • Sia, Daniela|||0000-0002-9000-611X
  • Mazzaferro, Vincenzo|||0000-0002-4013-8085
  • Esteller, M.|||0000-0003-4490-6093
  • Llovet, Josep M.|||0000-0003-0547-2667
The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. We assessed transcriptome data, whole-exome sequencing data and DNA methylome profiling of 520 HCC patients from two independent cohorts to identify distinct molecular traits of patients with AFP-high tumours (serum concentration.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT), initial results from an international prospective study

  • Bancroft, Elizabeth|||0000-0002-5482-5660
  • Page, Elizabeth C.
  • Brook, Mark N.|||0000-0002-8969-2378
  • Thomas, Sarah
  • Taylor, Natalie
  • Pope, Jennifer
  • McHugh, Jana
  • Jones, Ann-Britt
  • Karlsson, Questa
  • Merson, Susan
  • Ong, Kai Ren
  • Hoffman, Jonathan
  • Huber, Camilla
  • Maehle, Lovise
  • Grindedal, Eli Marie
  • Stormorken, Astrid
  • Evans, Gareth|||0000-0002-8482-5784
  • Rothwell, Jeanette
  • Lalloo, Fiona
  • Brady, Angela F.
  • Bartlett, Marion
  • Snape, Katie
  • Hanson, Helen
  • James, Paul|||0000-0002-4361-4657
  • McKinley, Joanne
  • Mascarenhas, Lyon
  • Syngal, Sapna
  • Ukaegbu, Chinedu
  • Side, Lucy
  • Thomas, Tessy
  • Barwell, Julian
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Izatt, Louise|||0000-0003-1258-4843
  • Suri, Mohnish|||0000-0001-9037-701X
  • Macrae, Finlay A.
  • Poplawski, Nicola
  • Chen-Shtoyerman, Rakefet|||0000-0002-5055-5907
  • Ahmed, Munaza
  • Musgrave, Hannah
  • Nicolai, Nicola|||0000-0002-5718-2699
  • Greenhalgh, Lynn
  • Brewer, Carole
  • Pachter, Nicholas
  • Spigelman, Allan D.
  • Azzabi, Ashraf
  • Helfand, Brian T.
  • Halliday, Dorothy
  • Buys, Saundra|||0000-0003-4120-5697
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Donaldson, Alan|||0000-0001-9193-4172
  • Cooney, Kathleen A.
  • Harris, Marion
  • McGrath, John
  • Davidson, Rosemarie
  • Taylor, Amy
  • Cooke, Peter
  • Myhill, Kathryn
  • Hogben, Matthew
  • Aaronson, Neil K.
  • Ardern-Jones, Audrey
  • Bangma, Chris H.
  • Castro, Elena|||0000-0002-3691-6454
  • Dearnaley, David|||0000-0002-3954-2806
  • Dias, Alexander
  • Dudderidge, Tim|||0000-0001-6373-3613
  • Eccles, Diana M.|||0000-0002-9935-3169
  • Green, Kate
  • Eyfjord, Jorunn
  • Falconer, Alison
  • Foster, Christopher S.
  • Gronberg, Henrik
  • Hamdy, Freddie C.|||0000-0003-2627-2154
  • Johannsson, Oskar
  • Khoo, Vincent
  • Lilja, Hans|||0000-0001-5871-7846
  • Lindeman, Geoffrey J.|||0000-0001-9386-2416
  • Lubinski, Jan|||0000-0003-2931-3003
  • Axcrona, Karol|||0000-0002-5011-0107
  • Mikropoulos, Christos|||0000-0001-8070-2851
  • Mitra, Anita V.
  • Moynihan, Clare
  • Ni Raghallaigh, Holly
  • Rennert, Gad|||0000-0002-8512-068X
  • Collier, Rebecca
  • Offman, Judith|||0000-0001-5604-1635
  • Kote-Jarai, Zsofia|||0000-0002-6329-5155
  • Eeles, Rosalind|||0000-0002-3698-6241
Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer. The IMPACT study is prospectively assessing prostate-specific antigen (PSA) screening in men with germline mismatch repair pathogenic variants. Here, we report the usefulness of PSA screening, prostate cancer incidence, and tumour characteristics after the first screening round in men with and without these germline pathogenic variants. The IMPACT study is an international, prospective study. Men aged 40-69 years without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene, and age-matched male controls who tested negative for a familial pathogenic variant in these genes were recruited from 34 genetic and urology clinics in eight countries, and underwent a baseline PSA screening. Men who had a PSA level higher than 3·0 ng/mL were offered a transrectal, ultrasound-guided, prostate biopsy and a histopathological analysis was done. All participants are undergoing a minimum of 5 years' annual screening. The primary endpoint was to determine the incidence, stage, and pathology of screening-detected prostate cancer in carriers of pathogenic variants compared with non-carrier controls. We used Fisher's exact test to compare the number of cases, cancer incidence, and positive predictive values of the PSA cutoff and biopsy between carriers and non-carriers and the differences between disease types (ie, cancer vs no cancer, clinically significant cancer vs no cancer). We assessed screening outcomes and tumour characteristics by pathogenic variant status. Here we present results from the first round of PSA screening in the IMPACT study. This study is registered with , , and is now closed to accrual. Between Sept 28, 2012, and March 1, 2020, 828 men were recruited (644 carriers of mismatch repair pathogenic variants [204 carriers of MLH1, 305 carriers of MSH2, and 135 carriers of MSH6 ] and 184 non-carrier controls [65 non-carriers of MLH1, 76 non-carriers of MSH2, and 43 non-carriers of MSH6 ]), and in order to boost the sample size for the non-carrier control groups, we randomly selected 134 non-carriers from the BRCA1 and BRCA2 cohort of the IMPACT study, who were included in all three non-carrier cohorts. Men were predominantly of European ancestry (899 [93%] of 953 with available data), with a mean age of 52·8 years (SD 8·3). Within the first screening round, 56 (6%) men had a PSA concentration of more than 3·0 ng/mL and 35 (4%) biopsies were done. The overall incidence of prostate cancer was 1·9% (18 of 962; 95% CI 1·1-2·9). The incidence among MSH2 carriers was 4·3% (13 of 305; 95% CI 2·3-7·2), MSH2 non-carrier controls was 0·5% (one of 210; 0·0-2·6), MSH6 carriers was 3·0% (four of 135; 0·8-7·4), and none were detected among the MLH1 carriers, MLH1 non-carrier controls, and MSH6 non-carrier controls. Prostate cancer incidence, using a PSA threshold of higher than 3·0 ng/mL, was higher in MSH2 carriers than in MSH2 non-carrier controls (4·3% vs 0·5%; p=0·011) and MSH6 carriers than MSH6 non-carrier controls (3·0% vs 0%; p=0·034). The overall positive predictive value of biopsy using a PSA threshold of 3·0 ng/mL was 51·4% (95% CI 34·0-68·6), and the overall positive predictive value of a PSA threshold of 3·0 ng/mL was 32·1% (20·3-46·0). After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer compared with age-matched non-carrier controls. These findings support the use of targeted PSA screening in these men to identify those with clinically significant prostate cancer. Further annual screening rounds will need to confirm these findings.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

  • Zeng, Chenjie
  • Guo, Xingyi
  • Long, Jirong
  • Kuchenbaecker, Karoline B.
  • Droit, Arnaud
  • Michailidou, Kyriaki
  • Ghoussaini, Maya
  • Kar, Siddhartha
  • Freeman, Adam
  • Hopper, John L.
  • Milne, Roger L.|||0000-0001-5764-7268
  • Bolla, Manjeet K.|||0000-0002-4351-9326
  • Wang, Qin
  • Dennis, Joe|||0000-0003-4591-1214
  • Agata, Simona
  • Ahmed, Shahana
  • Aittomäki, Kristiina
  • Andrulis, Irene L.|||0000-0002-4226-6435
  • Anton-Culver, Hoda
  • Antonenkova, Natalia N.
  • Arason, Adalgeir|||0000-0003-0480-886X
  • Arndt, Volker|||0000-0001-9320-8684
  • Arun, Banu K.
  • Arver, Brita
  • Bacot, Francois
  • Barrowdale, Daniel|||0000-0003-1661-3939
  • Baynes, Caroline
  • Beeghly-Fadiel, Alicia|||0000-0001-9913-732X
  • Benitez, Javier|||0000-0002-0923-7202
  • Bermisheva, Marina
  • Blomqvist, Carl
  • Blot, William
  • Bogdanova, Natalia V.
  • Bojesen, Stig E.
  • Bonanni, Bernardo|||0000-0003-3589-2128
  • Borresen-Dale, Anne-Lise
  • Brand, Judith S.
  • Brauch, Hiltrud|||0000-0001-7531-2736
  • Brennan, Paul
  • Brenner, Hermann
  • Broeks, Annegien
  • Brüning, Thomas
  • Burwinkel, Barbara
  • Buys, Saundra|||0000-0003-4120-5697
  • Cai, Qiuyin
  • Caldes, Trinidad
  • Campbell, Ian|||0000-0002-7773-4155
  • Carpenter, Jane
  • Chang-Claude, Jenny
  • Choi, Ji-Yeob
  • Claes, Kathleen|||0000-0003-0841-7372
  • Clarke, Christine L.
  • Cox, Angela
  • Cross, Simon S.
  • Czene, Kamila
  • Daly, Mary B.
  • Hoya, Miguel de la|||0000-0002-8113-1410
  • De Leeneer, Kim
  • Devilee, Peter|||0000-0002-8023-2009
  • Diez, Orland|||0000-0001-7339-0570
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Doody, Michele
  • Dorfling, Cecilia M.
  • Dörk, Thilo|||0000-0002-9458-0282
  • dos-Santos-Silva, Isabel
  • Dumont, Martine
  • Dwek, Miriam
  • Dworniczak, Bernd
  • Egan, Kathleen
  • Eilber, Ursula
  • Einbeigi, Zakaria
  • Ejlertsen, Bent
  • Ellis, Steve
  • Frost, Debra
  • Lalloo, Fiona
  • Fasching, Peter A.
  • Figueroa, Jonine
  • Flyger, Henrik
  • Friedlander, Michael|||0000-0003-3090-795X
  • Friedman, Eitan|||0000-0002-6745-1733
  • Gambino, Gaetana
  • Gao, Yu-Tang
  • Garber, Judy
  • García-Closas, Montserrat
  • Gehrig, Andrea
  • Damiola, Francesca
  • Lesueur, Fabienne|||0000-0001-7404-4549
  • Mazoyer, Sylvie
  • Stoppa-Lyonnet, Dominique
  • Giles, Graham G.
  • Godwin, Andrew K.|||0000-0002-3987-9580
  • Goldgar, David E.
  • González-Neira, Anna
  • Greene, Mark H.|||0000-0003-1852-9239
  • Guénel, Pascal
  • Haeberle, Lothar
  • Haiman, Christopher A.
  • Hallberg, Emily
  • Hamann, Ute|||0000-0001-6705-7624
  • Hansen, Thomas V. O.
  • Hart, Steven
  • Hartikainen, Jaana M.
  • Hartman, Mikael
  • Hassan, Norhashimah
  • Healey, Sue
  • Hogervorst, Frans B. L.
  • Verhoef, Senno
  • Hendricks, Carolyn B.
  • Hillemanns, Peter
  • Hollestelle, Antoinette
  • Hulick, Peter J.
  • Hunter, David J.
  • Imyanitov, Evgeny N.
  • Isaacs, Claudine|||0000-0002-9646-1260
  • Ito, Hidemi
  • Jakubowska, Anna|||0000-0002-5650-0501
  • Janavicius, Ramunas
  • Jaworska-Bieniek, Katarzyna
  • Jensen, Uffe Birk
  • John, Esther M.
  • Joly Beauparlant, Charles
  • Jones, Michael
  • Kabisch, Maria
  • Kang, Daehee
  • Karlan, Beth Y.|||0000-0002-9451-2933
  • Kauppila, Saila
  • Kerin, Michael J.
  • Khan, Sofia
  • Khusnutdinova, Elza
  • Knight, Julia A.
  • Konstantopoulou, Irene|||0000-0002-0470-0309
  • Kraft, Peter
  • Kwong, Ava
  • Laitman, Yael
  • Lambrechts, Diether
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Le Marchand, Loic
  • Lee, Chuen Neng
  • Lee, Min Hyuk
  • Lester, Jenny
  • Li, Jingmei
  • Liljegren, Annelie
  • Lindblom, Annika
  • Lophatananon, Artitaya
  • Lubinski, Jan|||0000-0003-2931-3003
  • Mai, Phuong L.
  • Mannermaa, Arto
  • Manoukian, Siranoush
  • Margolin, Sara
  • Marme, Frederik
  • Matsuo, Keitaro
  • McGuffog, Lesley|||0000-0003-1237-0546
  • Meindl, Alfons
  • Menegaux, Florence
  • Montagna, Marco
  • Muir, Kenneth
  • Mulligan, Anna Marie
  • Nathanson, Katherine L.|||0000-0002-6740-0901
  • Neuhausen, Susan L.|||0000-0001-5053-0390
  • Nevanlinna, Heli|||0000-0002-0916-2976
  • Newcomb, Polly A.
  • Nord, Silje
  • Nussbaum, Robert L.|||0000-0003-3445-8880
  • Offit, Kenneth
  • Olah, Edith
  • Olopade, Olufunmilayo I.|||0000-0002-9936-1599
  • Olswold, Curtis
  • Osorio, Ana|||0000-0001-8124-3984
  • Papi, Laura
  • Park-Simon, Tjoung-Won
  • Paulsson-Karlsson, Ylva
  • Peeters, Stephanie
  • Peissel, Bernard|||0000-0001-9233-3571
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Peto, Julian|||0000-0002-1685-8912
  • Pfeiler, Georg
  • Phelan, Catherine M.
  • Presneau, Nadege
  • Radice, Paolo|||0000-0001-6298-4111
  • Rahman, Nazneen
  • Ramus, Susan J.|||0000-0003-0005-7798
  • Rashid, Muhammad Usman
  • Rennert, Gad|||0000-0002-8512-068X
  • Rhiem, Kerstin
  • Rudolph, Anja
  • Salani, Ritu
  • Sangrajrang, Suleeporn
  • Sawyer, Elinor J.
  • Schmidt, Marjanka K.|||0000-0002-2228-429X
  • Schmutzler, Rita K.
  • Schoemaker, Minouk J.
  • Schürmann, Peter
  • Seynaeve, Caroline
  • Shen, Chen-Yang
  • Shrubsole, Martha J.
  • Shu, Xiao-Ou
  • Sigurdson, Alice
  • Singer, Christian F.
  • Slager, Susan|||0000-0002-5173-4712
  • Soucy, Penny
  • Southey, Melissa C.|||0000-0002-6313-9005
  • Steinemann, Doris|||0000-0001-8797-0816
  • Swerdlow, Anthony
  • Szabo, Csilla I.
  • Tchatchou, Sandrine
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Teo, Soo|||0000-0002-0444-590X
  • Terry, Mary Beth
  • Tessier, Daniel C.
  • Teule, Alex|||0000-0003-0028-7200
  • Thomassen, Mads
  • Tihomirova, Laima
  • Tischkowitz, Marc
  • Toland, Amanda Ewart|||0000-0002-0271-1792
  • Tung, Nadine
  • Turnbull, Clare
  • van den Ouweland, Ans M. W.
  • van Rensburg, Elizabeth J.|||0000-0003-2077-230X
  • ven den Berg, David
  • Vijai, Joseph
  • Wang-Gohrke, Shan
  • Weitzel, Jeffrey N.
  • Whittemore, Alice S.
  • Winqvist, Robert
  • Wong, Tien Y.
  • Wu, Anna H.
  • Yannoukakos, Drakoulis
  • Yu, Jyh-Cherng
  • Pharoah, Paul D.P.|||0000-0001-8494-732X
  • Hall, Per
  • Chenevix-Trench, Georgia
  • Dunning, Alison M.
  • Simard, Jacques|||0000-0001-6906-3390
  • Couch, Fergus J.
  • Antoniou, Antonis C.
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Zheng, Wei|||0000-0003-1226-070X
Multiple recent genome-wide association studies (GWAS) have identified a single nucleotide polymorphism (SNP), rs10771399, at 12p11 that is associated with breast cancer risk. We performed a fine-scale mapping study of a 700 kb region including 441 genotyped and more than 1300 imputed genetic variants in 48,155 cases and 43,612 controls of European descent, 6269 cases and 6624 controls of East Asian descent and 1116 cases and 932 controls of African descent in the Breast Cancer Association Consortium (BCAC; ), and in 15,252 BRCA1 mutation carriers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Stepwise regression analyses were performed to identify independent association signals. Data from the Encyclopedia of DNA Elements project (ENCODE) and the Cancer Genome Atlas (TCGA) were used for functional annotation. Analysis of data from European descendants found evidence for four independent association signals at 12p11, represented by rs7297051 (odds ratio (OR) = 1.09, 95 % confidence interval (CI) = 1.06-1.12; P = 3 × 10 -9), rs805510 (OR = 1.08, 95 % CI = 1.04-1.12, P = 2 × 10 -5), and rs1871152 (OR = 1.04, 95 % CI = 1.02-1.06; P = 2 × 10 -4) identified in the general populations, and rs113824616 (P = 7 × 10 -5) identified in the meta-analysis of BCAC ER-negative cases and BRCA1 mutation carriers. SNPs rs7297051, rs805510 and rs113824616 were also associated with breast cancer risk at P < 0.05 in East Asians, but none of the associations were statistically significant in African descendants. Multiple candidate functional variants are located in putative enhancer sequences. Chromatin interaction data suggested that PTHLH was the likely target gene of these enhancers. Of the six variants with the strongest evidence of potential functionality, rs11049453 was statistically significantly associated with the expression of PTHLH and its nearby gene CCDC91 at P < 0.05. This study identified four independent association signals at 12p11 and revealed potentially functional variants, providing additional insights into the underlying biological mechanism(s) for the association observed between variants at 12p11 and breast cancer risk. The online version of this article (doi:10.1186/s13058-016-0718-0) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Interim Results from the IMPACT Study, Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

  • Page, Elizabeth C.
  • Bancroft, Elizabeth|||0000-0002-5482-5660
  • Brook, Mark N.|||0000-0002-8969-2378
  • Assel, Melissa
  • Hassan Al Battat, Mona
  • Thomas, Sarah
  • Taylor, Natalie
  • Chamberlain, Anthony
  • Pope, Jennifer
  • Raghallaigh, Holly Ni
  • Evans, Gareth|||0000-0002-8482-5784
  • Rothwell, Jeanette
  • Maehle, Lovise
  • Grindedal, Eli Marie
  • James, Paul|||0000-0002-4361-4657
  • Mascarenhas, Lyon
  • McKinley, Joanne
  • Side, Lucy
  • Thomas, Tessy
  • van Asperen, Christi
  • Vasen, Hans|||0000-0003-2682-2603
  • Kiemeney, Lambertus A.
  • Ringelberg, Janneke
  • Jensen, Thomas Dyrso
  • Osther, Palle Jörn Sloth|||0000-0001-7962-1640
  • Helfand, Brian T.
  • Genova, Elena
  • Oldenburg, Rogier A.
  • Cybulski, Cezary|||0000-0002-2819-3057
  • Wokolorczyk, Dominika
  • Ong, Kai-Ren
  • Huber, Camilla
  • Lam, Jimmy
  • Taylor, Louise
  • Salinas, Monica
  • Feliubadaló, Lidia|||0000-0002-1736-0112
  • Oosterwijk, Jan C.
  • van Zelst-Stams, Wendy
  • Cook, Jackie
  • Rosario, Derek J.|||0000-0002-9086-3592
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Powers, Jacquelyn
  • Buys, Saundra|||0000-0003-4120-5697
  • O'Toole, Karen
  • Ausems, Margreet G. E. M.
  • Schmutzler, Rita K.
  • Rhiem, Kerstin
  • Izatt, Louise|||0000-0003-1258-4843
  • Tripathi, Vishakha
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Cardoso, Marta|||0000-0002-3633-1659
  • Foulkes, William|||0000-0001-7427-4651
  • Aprikian, Armen
  • van Randeraad, Heleen
  • Davidson, Rosemarie
  • Longmuir, Mark
  • Ruijs, Marielle W.G.
  • Helderman van den Enden, Apollonia T.J.M.
  • Adank, Muriel A.
  • Williams, Rachel|||0000-0001-6353-944X
  • Andrews, Lesley
  • Murphy, Declan G.
  • Halliday, Dorothy
  • Walker, Lisa
  • Liljegren, Annelie
  • Carlsson, Stefan
  • Azzabi, Ashraf
  • Jobson, Irene
  • Morton, Catherine
  • Shackleton, Kylie
  • Snape, Katie
  • Hanson, Helen
  • Harris, Marion
  • Tischkowitz, Marc
  • Taylor, Amy
  • Kirk, Judy
  • Susman, Rachel
  • Chen-Shtoyerman, Rakefet|||0000-0002-5055-5907
  • Spigelman, Allan
  • Pachter, Nicholas
  • Ahmed, Munaza
  • Ramon y Cajal, Teresa|||0000-0003-3490-3585
  • Zgajnar, Janez
  • Brewer, Carole
  • Gadea, Neus|||0000-0002-6736-3979
  • Brady, Angela F.
  • Van Os, Theo
  • Gallagher, David
  • Johannsson, Oskar
  • Donaldson, Alan|||0000-0001-9193-4172
  • Barwell, Julian
  • Nicolai, Nicola|||0000-0002-5718-2699
  • Friedman, Eitan|||0000-0002-6745-1733
  • Obeid, Elias|||0000-0001-5120-9435
  • Greenhalgh, Lynn
  • Murthy, Vedang|||0000-0001-6011-9319
  • Copakova, Lucia
  • Saya, Sibel|||0000-0002-4796-6852
  • McGrath, John
  • Cooke, Peter
  • Rønlund, Karina
  • Richardson, Kate
  • Henderson, Alex
  • Teo, Soo|||0000-0002-0444-590X
  • Arun, Banu K.
  • Kast, Karin|||0000-0001-6531-755X
  • Dias, Alexander
  • Aaronson, Neil K.
  • Ardern-Jones, Audrey
  • Bangma, Chris H.
  • Castro, Elena|||0000-0002-3691-6454
  • Dearnaley, David|||0000-0002-3954-2806
  • Eccles, Diana M.|||0000-0002-9935-3169
  • Tricker, Karen
  • Eyfjord, Jorunn
  • Falconer, Alison
  • Foster, Christopher
  • Gronberg, Henrik
  • Hamdy, Freddie C.|||0000-0003-2627-2154
  • Stefansdottir, Vigdis|||0000-0003-4451-3126
  • Khoo, Vincent
  • Lindeman, Geoffrey J.|||0000-0001-9386-2416
  • Lubinski, Jan|||0000-0003-2931-3003
  • Axcrona, Karol|||0000-0002-5011-0107
  • Mikropoulos, Christos|||0000-0001-8070-2851
  • Mitra, Anita
  • Moynihan, Clare
  • Rennert, Gad|||0000-0002-8512-068X
  • Suri, Mohnish|||0000-0001-9037-701X
  • Wilson, Penny
  • Dudderidge, Tim|||0000-0001-6373-3613
  • Offman, Judith|||0000-0001-5604-1635
  • Kote-Jarai, Zsofia|||0000-0002-6329-5155
  • Vickers, Andrew J.|||0000-0003-1525-6503
  • Lilja, Hans|||0000-0001-5871-7846
  • Eeles, Rosalind|||0000-0002-3698-6241
Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

  • Coignard, Juliette
  • Beesley, Jonathan
  • O'Mara, Tracy A.
  • Diez Gibert, Orland
  • Lopez Fernandez, Adrià
  • Dennis, Joe
  • Tyrer, Jonathan
  • Lush, Michael
Càncer de mama; Genètica del càncer; Factors de risc, Cáncer de mama; Genética del cáncer; Factores de riesgo, Breast cancer; Cancer genetics; Risk factors, Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in general population studies. Other mutation carrier-specific susceptibility variants may exist but studies of mutation carriers have so far been underpowered. We conduct a novel case-only genome-wide association study comparing genotype frequencies between 60,212 general population BC cases and 13,007 cases with BRCA1 or BRCA2 mutations. We identify robust novel associations for 2 variants with BC for BRCA1 and 3 for BRCA2 mutation carriers, P < 10−8, at 5 loci, which are not associated with risk in the general population. They include rs60882887 at 11p11.2 where MADD, SP11 and EIF1, genes previously implicated in BC biology, are predicted as potential targets. These findings will contribute towards customising BC polygenic risk scores for BRCA1 and BRCA2 mutation carriers.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program

  • Janin, Maxime
  • Ortiz‑Barahona, Vanessa
  • Castro de Moura, Manuel
  • Martínez‑Cardús, Anna
  • Llinàs‑Arias, Pere
  • Soler, Marta
  • Arias Piñeiro, Alexandra
  • Cuartas Maza, Ma Isabel
  • Seoane Suarez, Joan
Resultado clínico; Epitranscriptómica; Glioma, Clinical outcome; Epitranscriptomics; Glioma, Resultat clínic; Epitranscriptòmica; Glioma, Tumors have aberrant proteomes that often do not match their corresponding transcriptome profiles. One possible cause of this discrepancy is the existence of aberrant RNA modification landscapes in the so-called epitranscriptome. Here, we report that human glioma cells undergo DNA methylation-associated epigenetic silencing of NSUN5, a candidate RNA methyltransferase for 5-methylcytosine. In this setting, NSUN5 exhibits tumor-suppressor characteristics in vivo glioma models. We also found that NSUN5 loss generates an unmethylated status at the C3782 position of 28S rRNA that drives an overall depletion of protein synthesis, and leads to the emergence of an adaptive translational program for survival under conditions of cellular stress. Interestingly, NSUN5 epigenetic inactivation also renders these gliomas sensitive to bioactivatable substrates of the stress-related enzyme NQO1. Most importantly, NSUN5 epigenetic inactivation is a hallmark of glioma patients with long-term survival for this otherwise devastating disease., This work was supported by a European Research Council (ERC) Advanced Grant under the European Community’s Seventh Framework Program (FP7/2007-2013)/ERC Grant Agreement No. 268626—EPINORC project (to M. Esteller), the Ministerio de Economía y Competitividad (MINECO) under Grant No. SAF2014-55000-R (to M. Esteller) and the Instituto de Salud Carlos III (ISCIII), under the FIS PI16/01278 Project (to J. Seoane), the Integrated Project of Excellence no. PIE13/00022 (ONCOPROFILE) (to M. Esteller), CIBER 2016 CB16/12/00312 (CIBERONC) (to M. Esteller), co-financed by the European Development Regional Fund, ‘A way to achieve Europe’ ERDF, the AGAUR—Catalan Government (Project No. 2009SGR1315 and 2014SGR633) (to M. Esteller), the Cellex Foundation (to M. Esteller), Obra Social “La Caixa” (to M. Esteller), the CERCA Program and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) (to M. Esteller) and a grant from the National Health and Medical Research Council of Australia (APP1061551, to TP). M.W. Boudreau is a member of the NIH Chemistry-Biology Interface Training Program (T32-GM070421).